Ubs Asset Management Americas Inc Biotechnology

Ubs Asset Management Americas Inc

$381 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
VRTX Vertex Pharmaceuticals Inc	$113B	$1.14 Billion 0.3% of portfolio	2,441,468	Q3 2024 Reduced 5.53%
REGN Regeneron Pharmaceuticals, Inc.	$72.4B	$794 Million 0.21% of portfolio	755,112	Q3 2024 Reduced 10.92%
MRNA Moderna, Inc.	$16.2B	$260 Million 0.07% of portfolio	3,890,812	Q3 2024 Added 0.51%
ALNY Alnylam Pharmaceuticals, Inc.	$34.3B	$194 Million 0.05% of portfolio	706,231	Q3 2024 Reduced 15.46%
DNLI Denali Therapeutics Inc.	$2.98B	$109 Million 0.03% of portfolio	3,749,486	Q3 2024 Added 63.18%
INCY Incyte Corp	$16.1B	$91.2 Million 0.02% of portfolio	1,379,465	Q3 2024 Reduced 24.13%
RPRX Royalty Pharma PLC	$13.6B	$84.1 Million 0.02% of portfolio	2,972,201	Q3 2024 Added 6.25%
UTHR United Therapeutics Corp	$16.9B	$76.2 Million 0.02% of portfolio	212,657	Q3 2024 Reduced 12.83%
BMRN Biomarin Pharmaceutical Inc	$11.5B	$61.9 Million 0.02% of portfolio	880,453	Q3 2024 Reduced 13.09%
TECH Bio Techne Corp	$3.02B	$60.3 Million 0.02% of portfolio	754,344	Q3 2024 Added 2.76%
PCVX Vaxcyte, Inc.	$5.32B	$46.6 Million 0.01% of portfolio	408,274	Q3 2024 Added 38.04%
ARWR Arrowhead Pharmaceuticals, Inc.	$2.2B	$41.7 Million 0.01% of portfolio	2,154,250	Q3 2024 Reduced 5.93%
KRYS Krystal Biotech, Inc.	$3.97B	$40.9 Million 0.01% of portfolio	224,945	Q3 2024 Reduced 10.65%
SRPT Sarepta Therapeutics, Inc.	$10.2B	$33.5 Million 0.01% of portfolio	268,203	Q3 2024 Reduced 11.04%
CRSP Crispr Therapeutics Ag	$3.39B	$31.8 Million 0.01% of portfolio	676,326	Q3 2024 Reduced 2.54%
INSM Insmed Inc	$10.6B	$30.9 Million 0.01% of portfolio	422,936	Q3 2024 Reduced 3.27%
VKTX Viking Therapeutics, Inc.	$2.68B	$29.9 Million 0.01% of portfolio	472,244	Q3 2024 Reduced 1.49%
ROIV Roivant Sciences Ltd.	$7.87B	$26.6 Million 0.01% of portfolio	2,307,178	Q3 2024 Added 49.41%
ACLX Arcellx, Inc.	$2.76B	$23.6 Million 0.01% of portfolio	282,855	Q3 2024 Reduced 8.87%
HALO Halozyme Therapeutics, Inc.	$7.77B	$22.8 Million 0.01% of portfolio	397,833	Q3 2024 Reduced 7.91%
ARGX Argenx Se	$35.9B	$22.2 Million 0.01% of portfolio	40,842	Q3 2024 Added 4,344.18%
BNTX Bio N Tech Se	$28.7B	$21.9 Million 0.01% of portfolio	184,334	Q3 2024 Reduced 20.39%
BPMC Blueprint Medicines Corp	$6.86B	$21.1 Million 0.01% of portfolio	227,911	Q3 2024 Reduced 24.5%
EXEL Exelixis, Inc.	$10.4B	$21 Million 0.01% of portfolio	810,541	Q3 2024 Reduced 6.39%
KYMR Kymera Therapeutics, Inc.	$2.43B	$20.3 Million 0.01% of portfolio	428,529	Q3 2024 Reduced 1.16%
JAZZ Jazz Pharmaceuticals PLC	$7.65B	$19.4 Million 0.01% of portfolio	174,078	Q3 2024 Added 135.35%
IOVA Iovance Biotherapeutics, Inc.	$986M	$18.3 Million 0.0% of portfolio	1,946,842	Q3 2024 Reduced 2.39%
URGN Uro Gen Pharma Ltd.	$234M	$17 Million 0.0% of portfolio	1,341,072	Q3 2024 Added 1.6%
BBIO Bridge Bio Pharma, Inc.	$5.57B	$16.8 Million 0.0% of portfolio	660,265	Q3 2024 Reduced 6.49%
PTGX Protagonist Therapeutics, Inc	$1.85B	$16.5 Million 0.0% of portfolio	368,132	Q3 2024 Reduced 0.49%
RNA Avidity Biosciences, Inc.	$1.55B	$16 Million 0.0% of portfolio	348,841	Q3 2024 Reduced 0.43%
RXRX Recursion Pharmaceuticals, Inc.	$1.32B	$14.1 Million 0.0% of portfolio	2,140,750	Q3 2024 Added 2.05%
NUVL Nuvalent, Inc.	$3.53B	$14.1 Million 0.0% of portfolio	137,821	Q3 2024 Reduced 7.26%
CYTK Cytokinetics Inc	$4.78B	$14.1 Million 0.0% of portfolio	266,756	Q3 2024 Added 5.88%
CRNX Crinetics Pharmaceuticals, Inc.	$2.09B	$13.9 Million 0.0% of portfolio	271,747	Q3 2024 Added 4.13%
ABCL Ab Cellera Biologics Inc.	$992M	$11.9 Million 0.0% of portfolio	4,590,103	Q3 2024 Reduced 0.19%
RYTM Rhythm Pharmaceuticals, Inc.	$3.22B	$11.8 Million 0.0% of portfolio	225,373	Q3 2024 Reduced 4.68%
IONS Ionis Pharmaceuticals Inc	$4.93B	$11.4 Million 0.0% of portfolio	285,697	Q3 2024 Reduced 10.8%
ARVN Arvinas, Inc.	$965M	$10.6 Million 0.0% of portfolio	430,484	Q3 2024 Reduced 0.16%
ADMA Adma Biologics, Inc.	$3.16B	$10.2 Million 0.0% of portfolio	509,967	Q3 2024 Reduced 4.85%
IDYA Ideaya Biosciences, Inc.	$1.14B	$10.1 Million 0.0% of portfolio	318,496	Q3 2024 Added 1.99%
RARE Ultragenyx Pharmaceutical Inc.	$3.09B	$9.87 Million 0.0% of portfolio	177,756	Q3 2024 Added 0.54%
BEAM Beam Therapeutics Inc.	$1.83B	$9.83 Million 0.0% of portfolio	401,286	Q3 2024 Reduced 4.36%
RVMD Revolution Medicines, Inc.	$3.59B	$9.79 Million 0.0% of portfolio	216,026	Q3 2024 Reduced 10.53%
NTLA Intellia Therapeutics, Inc.	$835M	$9.45 Million 0.0% of portfolio	460,012	Q3 2024 Reduced 10.21%
CORT Corcept Therapeutics Inc	$6.43B	$9.36 Million 0.0% of portfolio	202,352	Q3 2024 Reduced 8.24%
PRTA Prothena Corp Public LTD CO	$733M	$8.81 Million 0.0% of portfolio	526,748	Q3 2024 Added 1,122.86%
IMVT Immunovant, Inc.	$3.55B	$8.55 Million 0.0% of portfolio	310,830	Q3 2024 Reduced 3.02%
TGTX Tg Therapeutics, Inc.	$4.54B	$6.87 Million 0.0% of portfolio	293,927	Q3 2024 Reduced 8.68%
XNCR Xencor Inc	$1.17B	$6.69 Million 0.0% of portfolio	332,876	Q3 2024 Reduced 2.05%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.